PEAK6
VRTX icon

PEAK6’s Vertex Pharmaceuticals VRTX Stock Holding History

PEAK6’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,600
Closed -$12.5M – 3360
2025
Q4 		$12.5M Sell
27,600
-15,700
-36% -$6.77M 0.02% 546
2025
Q3 		$17M Sell
43,300
-15,200
-26% -$6.35M 0.02% 480
2025
Q2 		$26M Buy
58,500
+45,200
+340% +$20.8M 0.05% 321
2025
Q1 		$6.45M Buy
13,300
+2,300
+21% +$1.07M 0.01% 774
2024
Q4 		$4.43M Buy
+11,000
New +$5.1M 0.01% 974

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PEAK6's VRTX Position: Q2 2026 in Review

PEAK6 sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 3 shares — an estimated $1.33K sold.

PEAK6 first reported a position in VRTX in Q4 2024 and held it in 6 quarters. The position peaked at $13.6M in Q2 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • PEAK6 reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • PEAK6 sold 3 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.33K.
  • PEAK6 first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • PEAK6's Vertex Pharmaceuticals position peaked at $13.6M in Q2 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.